Trial Profile
Azacitidine and Venetoclax (ABT-199) as Induction Therapy With Venetoclax Maintenance in Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 03 Aug 2023 Planned primary completion date changed from 28 Jun 2023 to 15 May 2024.
- 01 Aug 2022 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 01 Aug 2022 Planned primary completion date changed from 28 Jun 2022 to 28 Jun 2023.